- Home
- SHMD vs PLX Comparison
SHMD vs PLX Comparison
Compare SHMD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHMD | PLX |
|---|---|---|
| Founded | 1864 | 1993 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 207.1M |
| IPO Year | 2023 | 1996 |
Fundamental Metrics
Financial Performance| Metric | SHMD | PLX |
|---|---|---|
| Price | $2.12 | $3.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 821.2K | ★ 922.4K |
| Earning Date | 11-25-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | $49.82 | $65.42 |
| Revenue Next Year | $48.26 | N/A |
| P/E Ratio | ★ N/A | $9.53 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.09 | $1.65 |
| 52 Week High | $10.65 | $3.19 |
Technical Indicators
Market Signals| Indicator | SHMD | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 34.49 | 63.93 |
| Support Level | $2.09 | $2.59 |
| Resistance Level | $3.65 | $3.19 |
| Average True Range (ATR) | 0.25 | 0.17 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 2.83 | 84.06 |
Price Performance
Historical ComparisonAbout SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.